Farmaci inalatori e dispnea nell asma e nella BPCO. Federico Lavorini
|
|
- Roy Gardner
- 5 years ago
- Views:
Transcription
1 Farmaci inalatori e dispnea nell asma e nella BPCO Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy
2 Presenter Disclosures F.L. has received in the last 3 years fees for lectures, advisory boards and reimbursements for attending meetings from the following pharma companies: - AstraZeneca, - Boehringer Ingelheim, - CIPLA, - Chiesi, - TEVA. The content of this talk represents the personal opinion of the presenter and does not necessarily represent the views or policy of the A.O.U. Careggi.
3 Am J Respir Crit Care Med 2012; 185(4): A subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. Corollary: The experience of dyspnea derives from interactions among multiple physiological, psychological, social and environmental factors, and may induce secondary physiological and behavioral responses.
4 A neurobiologic model of dyspnea in COPD Red arrows represent neural inputs reaching the somatosensory cortex and contribute to dyspnea Mahler DA and O Donnell DE (eds). Dyspnea, mechanisms, measurement and management 2014, CRC press.
5 Domains of Dyspnea Measurement (ATS 2012) Domain Definition Measurement Sensoryperceptual experience Affective distress Symptom impact or burden Measures of what breathing feels like «What does your breathing feel like and how bad is it?» Measures of how distressing breathing feels «How distressing or unpleasant is your breathing?» Measures of how dyspnea affects functional ability or health status «How does breathing affect your functional ability?» Single-item intensity ratings (e.g., Borg scale, VAS) Descriptors of specific sensations/clusters of related sensations Single-item ratings of severity of distress or unpleasantness Multi-item scales of emotional responses such as anxiety Ratings of disability or activity limitation (e.g., MRC dyspnea scale) Ratings of functional ability Scales of quality of life, health status Parshall MB, et al; ATS Committee. Am J Respir Crit Care Med 2012; 185:
6 Dyspnea Intensity: Sensory-Perceptual Domain
7 Exertional dyspnea in mild COPD is associated with the combined deleterious effects of higher ventilatory demand and abnormal dynamic ventilatory mechanics.
8 Lung Volume (% predicted TLC) Operating Lung Volumes during Exercise 120 Control (n=21) COPD (n=21) TLC 100 IC IRV VT EELV Rest Iso-V E Peak Rest Iso-V E Peak (78 L/min) (68 L/min)
9 Dyspnea (Borg Scale) Dyspnea Intensity with Increasing COPD Severity very severe Normal COPD (FEV 1 quartile): IV (worst) III II I (mildest) Ventilation (L/min) O Donnell DE, et al. Chest 2011.
10 Reduced chemosensitivity to hypoxia and blunted perception of dyspnea may predispose asthma patients to fatal attacks.
11 Dyspnea Quality: Sensory-Perceptual Domain
12 Dyspnea Intensity- Work rate Relationships Quality of Dyspnea during Exercise Breathing discomfort (Borg scale) maximal very, very severe very severe severe somewhat severe moderate slight very slight none COPD Health Work rate (% predicted maximum) Increased Work/Effort Unsatisfied Inspiration Inspiratory Difficulty Heavy Shallow Rapid Tight Chest Expiratory Difficulty * Selection frequency (% of group) p<0.05 vs Health * * * Health COPD O Donnell DE, et al. AJRCCM 1997;155:
13 Qualitative Descriptors of Exertional Dyspnea Increased Work/Effort Unsatisfied Inspiration Inspiratory Difficulty Heavy Normal COPD ILD * * * * Shallow Rapid * * Tight Chest Expiratory Difficulty *p<0.05 vs. Normal Selection Frequency (% of subjects) Selection Frequency (% of subjects) Selection Frequency (% of subjects) O Donnell DE, et al. J Appl Physiol 1998.
14 QUALITIES OF DYSPNEA Work/effort Arise through cortical motor command Tightness Stimulation of airway receptors Hunger for air Imbalance when ventilation increases ATS Statement. Am J Respir Crit Care Med 2012
15 Am J Respir Crit Care Med 2012; 185(4): many advances in the understanding of dyspnea mechanisms., but not yet translated into improved therapies. The field is plagued by studies involving small numbers of patients in what are often poorly controlled trials..there are still no drugs for which relief of dyspnea is an approved indication; rather, drugs are approved for the treatment of diseases in which dyspnea is a prominent symptom.
16 A neurobiologic model of dyspnea in COPD Anxyolitics Opiates Oxygen Furosemide Bronchodilators Heliox ICS
17 39 publications reviewed; only 17/39 with high strength of research design. Although limited literature examining the efficacy of nebulized medications for the treatment of dyspnea does exist, the results of these publications vary. Whereas some authors acknowledge that nebulized medications are effective for treating dyspnea, others have found widely inconsistent results or have cautioned against its use.
18 Comprehensive Approach to Management of Dyspnea in Advanced COPD Marciniuk DD, et al; CTS Committee. Can Respir J 2011; 18:
19 Stepwise Approach to Therapy Dyspnea (Borg Scale) very severe severe somewhat severe moderate slight very slight nothing at all Endurance exercise time (min) O Donnell DE. Med Sci Sports Exerc 2001;33:S647-S655.
20 Bronchodilators Bronchodilators improve different physiological correlates associated with dyspnea in COPD patients; Both LABAs and LAMAs improve lung hyperinflation at rest and during exercise and enhance exercise endurance; Medications from both bronchodilator classes have demonstrated significant improvements in dyspnea, related to exercise and daily activities compared with placebo. Parshall MB, et al; ATS Committee. Am J Respir Crit Care Med 2012; 185:
21 Lung Volume (%pred TLC) Improvements in Respiratory Mechanics during Exercise in Response to Tiotropium Tidal Pes / V T (cmh 2 0/L) Pre-dose IC Post-dose normal Pleural Pressure (cmh 2 0) VO 2 (% predicted max) Bronchodilator therapy was associated with a consistent reduction in operating lung volumes with improved effort-displacement ratios. Adapted from O Donnell DE, et al. J Appl Physiol 2006;101:
22 Improvements in dyspnea with bronchodilators in COPD Constant work rate cycle exercise Daily activities : Minimal clinically important difference
23 Most patients were at least moderately symptomatic based on BDI score
24 All patients TDI Responders (<1 Unit) IND/GLY provides significant benefits compared with tiotropium or SFC in patients with COPD who are experiencing dyspnea.
25
26 TDI: UMEC/VIL vs. UMEC Chest 2015, online
27 TDI: UMEC/VIL vs. VIL Chest 2015, online
28 Brit J Clin Pharmacol 2004 = 200 g salbutamol VHC = 400 g salbutamol VHC = 200 g salbutamol DPI = 400 g salbutamol DPI X = Placebo Lung function variables display lower variability and higher sensitivity to bronchodilation than dyspnea intensity (VAS score).
29 11 studies involving patients treated with either ICS or oral steroids; Some studies showing improved perception and other studies showing worsened perception of dyspnea after corticosteroid; Firm conclusions cannot be derived from the currently available data.
30 The total breath-holding time and the period of no respiratory sensation after furosemide inhalation were remarkably longer than those after placebo inhalation. These findings indicate that inhaled furosemide alleviates dyspneic sensation during breath-holding.
31 Aims: to investigate the effect of inhaled high (80 mg) doses furosemide on dyspnea intensity («breath disconfort» on a VAS) in healthy subjects. Dyspnea was induced by varying inspired PCO 2 while restricting minute ventilation. Furosemide deposition was optimised by controlling inspiratory flow ( ml/s) and Vt (15%VC) Conclusions: Neither wellcontrolled aerosol delivery, nor doubling the furosemide dose increase the proportion of responders.
32 Am J Respir Crit Care Med 2012; 185(4): Scientific respiratory societies advocate that oral and pareteral opiods be dosed and titrated for relief of refractory dispnea.
33 GINA guideline lacks specific guidance on treatment of refractory dyspnea in asthma.
34 «Opiodis modulate the perception of dyspnea by decreasing respiratory drive (and associate corollary discharge), altering central perception and/or decreasing anxiety»
35
36
37 Methods: healthy (fit) men with chest wall strapping (CWS) decreasing vital capacity by 20%; nebulized Fentanyl (FC 250 μg) or Placebo (PLA); constant work rate cycle exercise (85% of maximal incremental work rate). Conclusions: the results do not support a role for intrapulmonary opioids in the neuromodulation of dyspnea in health nor do they provide a rationale for nebulized fentanyl for treating dyspnea due to mild, restrictive pulmonary disorders.
38 Effects of Oxygen and Bronchodilators on Exercise BD: bronchodilators; PL: placebo; RA: room air. By combining the benefits of BD (reduced hyperinflation) and O 2 (reduced ventilatory drive), additive effects on dyspnea are observed in normoxic COPD patients.
39 Key Messages Dyspnea is a complex multi-dimensional symptom; No unique afferent source of dyspnea; Evaluation of dyspnea in the sensory, affective and impact domains is suggested; Increase dyspnea intensity during activity in COPD is, in part, related to increased sense of effort (increased motor drive and central corollary discharge); Interventions that relieve dyspnea intensity in COPD reduce central drive, improve respiratory mechanics/ muscle function and enhance neuromechanical coupling.
40 Key Messages (cont.) Literature review found mixed evidence regarding the use of nebulised medication for dyspnea relief; Differences in the Methods of inhalation, nebuliser systems, drugs properties, and patients characteristics may account for the discrepancies; Larger and long-term clinical trials are needed to assess which disease population may benefit most from nebulised drugs; In the meantime, the use of nebulised medications may be recommended if the advantages outweight the disadvantages.
41
Measuring Exertional Dyspnoea in Health and Disease
Measuring Exertional Dyspnoea in Health and Disease AIMS Prof. Denis O'Donnell Respiratory Investigation Unit Kingston General Hospital & Queen s University Kingston Richardson House 102 Stuart Street
More informationAmerican Thoracic Society Documents
American Thoracic Society Documents An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea Mark B. Parshall, Richard M. Schwartzstein, Lewis Adams,
More informationIn patients with symptomatic COPD, desirable. Assessment of Bronchodilator Efficacy in Symptomatic COPD* Is Spirometry Useful?
Assessment of Bronchodilator Efficacy in Symptomatic COPD* Is Spirometry Useful? Denis E. O Donnell, MD, FCCP Bronchodilator therapy in COPD is deemed successful if it improves ventilatory mechanics to
More informationThe problem with critical and non-critical inhaler errors
The problem with critical and non-critical inhaler errors Federico Lavorini MD, PhD Dept. Experimental and Clinical Medicine Careggi University Hospital Florence, Italy Presenter disclosures Federico Lavorini
More informationPulmonary deposition of inhaled drugs
Pulmonary deposition of inhaled drugs Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy Presenter Disclosures F.L. has received in the last 5 years
More informationExercise in the management of breathlessness
WHO Collaborating Centre for Palliative Care and Older People Exercise in the management of breathlessness Matthew Maddocks PhD Lecturer in Health Services Research NIHR Clinical Trials Fellow Maddocks
More informationPRACTICAL DYSPNEA MANAGEMENT Margot Sondermann BScPT, MEd. Palliative Consultant for End-Stage Lung Disease, Calgary Zone
PRACTICAL DYSPNEA MANAGEMENT Margot Sondermann BScPT, MEd. Palliative Consultant for End-Stage Lung Disease, Calgary Zone Faculty / Presenter Disclosure Faculty: Margot Sondermann Relationships with commercial
More informationPulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.
Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Plan Chronic Respiratory Disease Definition Factors Contributing
More informationExertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches Josuel Ora, Dennis Jensen and Denis E.
Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches Josuel Ora, Dennis Jensen and Denis E. O Donnell Respiratory Investigation Unit, Department of Medicine,
More informationWHAT ARE THE PHYSIOLOGICAL DETERMINANTS OF EXPIRATORY FLOW?
Lung Volume the physiology of breathing: OBSTRUCTIVE LUNG DISORDERS Dr. Andrew Fon MBBS FRACP Respiratory and Sleep Medicine Physician PhD Research Fellow Dept. of Thoracic Medicine, ROYAL ADELAIDE HOSPITAL
More informationCardiopulmonary Exercise Testing Cases
Canadian Respiratory Conference - 217 Cardiopulmonary Exercise Testing Cases Darcy D Marciniuk, MD FRCPC FCCP Associate Vice-President Research, University of Saskatchewan Professor, Respirology, Critical
More informationDECLINE OF RESTING INSPIRATORY CAPACITY IN COPD: THE IMPACT ON BREATHING PATTERN, DYSPNEA AND VENTILATORY CAPACITY DURING EXERCISE
Page 1 of 29 Body of text word count: 2,836 Abstract word count: 250 DECLINE OF RESTING INSPIRATORY CAPACITY IN COPD: THE IMPACT ON BREATHING PATTERN, DYSPNEA AND VENTILATORY CAPACITY DURING EXERCISE Authors:
More informationDyspnea: Evaluation and Management
Dyspnea: Evaluation and Management Sandra Whitlock, M.D. Four Seasons Palliative Care Course Handouts & Post Test o To download presentation handouts, click on the attachment icon o Presenter discloses
More informationTeacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology
Title: Spirometry Teacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology I. Measurements of Ventilation Spirometry A. Pulmonary Volumes 1. The tidal
More informationSpirometric Correlates of Improvement in Exercise Performance after Anticholinergic Therapy in Chronic Obstructive Pulmonary Disease
Spirometric Correlates of Improvement in Exercise Performance after Anticholinergic Therapy in Chronic Obstructive Pulmonary Disease DENIS E. O DONNELL, MIU LAM, and KATHERINE A. WEBB Respiratory Investigation
More informationDyspnea. Stephanie Lindsay
Dyspnea Stephanie Lindsay What is dyspnea? An unpleasant sensation of difficult, labored breathing Shortness of air Dyspnea is not the same as tachypnea therefore patients may not present with rapid breathing
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationImpacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Eur Respir Rev 2006; 15: 99, 37 41 DOI: 10.1183/09059180.00009903 CopyrightßERSJ Ltd 2006 Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance D.E. O Donnell ABSTRACT: The
More informationGestione della dispnea nell insufficienza respiratoria end-stage
Gestione della dispnea nell insufficienza respiratoria end-stage Salvatore M. Maggiore, MD, PhD salvatore.maggiore@unich.it Anesthesia and Intensive Care SS. Annunziata Hospital Gabriele d Annunzio University
More informationPFT Interpretation and Reference Values
PFT Interpretation and Reference Values September 21, 2018 Eric Wong Objectives Understand the components of PFT Interpretation of PFT Clinical Patterns How to choose Reference Values 3 Components Spirometry
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationBreathing and pulmonary function
EXPERIMENTAL PHYSIOLOGY EXPERIMENT 5 Breathing and pulmonary function Ying-ying Chen, PhD Dept. of Physiology, Zhejiang University School of Medicine bchenyy@zju.edu.cn Breathing Exercise 1: Tests of pulmonary
More informationEffects of Hyperoxia on Ventilatory Limitation During Exercise in Advanced Chronic Obstructive Pulmonary Disease
Effects of Hyperoxia on Ventilatory Limitation During Exercise in Advanced Chronic Obstructive Pulmonary Disease DENIS E. O DONNELL, CHRISTINE D ARSIGNY, and KATHERINE A. WEBB Respiratory Investigation
More informationShaping a Dynamic Future in Respiratory Practice. #DFResp
Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationThe effect of opioid use on pulmonary function test in advanced COPD patients
The effect of opioid use on pulmonary function test in advanced COPD patients Parinaz Koohi Habibi Dehkordi (1) Sayed Mahdi Ayat (1) Hamid Rouhi Boroujeni (2) Hamid Sohrabpour (3) Abbas Fadaei (4) (1)
More informationPULMONARY FUNCTION. VOLUMES AND CAPACITIES
PULMONARY FUNCTION. VOLUMES AND CAPACITIES The volume of air a person inhales (inspires) and exhales (expires) can be measured with a spirometer (spiro = breath, meter = to measure). A bell spirometer
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationObjectives. Objectives. Definition. Physiology. Evaluation of the Dyspneic Patient. B. Celli Disclaimer
Evaluation of the Dyspneic Patient Bartolome R. Celli Harvard Medical School Brigham and Women s Hospital Boston B. Celli Disclaimer No stocks or ownership in any company. No Tobacco funds No promotional
More informationSLEEP DISORDERED BREATHING AND CHRONIC LUNG DISEASE: UPDATE ON OVERLAP SYNDROMES
SLEEP DISORDERED BREATHING AND CHRONIC LUNG DISEASE: UPDATE ON OVERLAP SYNDROMES ROBERT OWENS, MD ASSISTANT CLINICAL PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA AT SAN DIEGO LA JOLLA, CA Robert L. Owens,
More informationOver the last several years various national and
Recommendations for the Management of COPD* Gary T. Ferguson, MD, FCCP Three sets of guidelines for the management of COPD that are widely recognized (from the European Respiratory Society [ERS], American
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationThe Importance of Pulmonary Rehabilitation
November 21, 2017 The Importance of Pulmonary Rehabilitation Presenter: George Pyrgos, MD 1 The importance of Pulmonary Rehabilitation George Pyrgos, MD Medical Director of the Angelos Lung Center at Medstar
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More information6- Lung Volumes and Pulmonary Function Tests
6- Lung Volumes and Pulmonary Function Tests s (PFTs) are noninvasive diagnostic tests that provide measurable feedback about the function of the lungs. By assessing lung volumes, capacities, rates of
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationPulmonary rehabilitation in severe COPD.
Pulmonary rehabilitation in severe COPD daniel.langer@faber.kuleuven.be Content Rehabilitation (how) does it work? How to train the ventilatory limited patient? Chronic Obstructive Pulmonary Disease NHLBI/WHO
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More information3 COPD Recognition and Diagnosis: Approach to the Patient with Respiratory Symptoms
William L. Eschenbacher, MD 3 COPD Recognition and Diagnosis: Approach to the Patient with Respiratory Symptoms Key Points 1. Patients who present with respiratory symptoms such as cough, sputum production,
More informationThe addition of non-invasive ventilation during exercise training in COPD patients. Enrico Clini and Michelle Chatwin
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationSam H Ahmedzai Academic Unit of Supportive Care Department of Oncology The University of Sheffield & Sheffield Teaching Hospitals NHS Foundation
Sam H Ahmedzai Academic Unit of Supportive Care Department of Oncology The University of Sheffield & Sheffield Teaching Hospitals NHS Foundation Trust Overview Which drugs? How much? How to give? Adverse
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationDyspnea: The top things you need to you know! Dr. Megan Sellick & Dr. Lawrence Lee Edmonton Zone Palliative Care Program
: The top things you need to you know! Dr. Megan Sellick & Dr. Lawrence Lee Edmonton Zone Palliative Care Program Faculty / Presenter Disclosure Faculty: Dr. Lawrence Lee Relationships with commercial
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationDr. A. Kerigan BREATHLESSNESS AT THE END OF LIFE
Dr. A. Kerigan BREATHLESSNESS AT THE END OF LIFE Faculty/Presenter Disclosure Faculty: Dr. A. Kerigan Relationships with commercial interests:* - Grants/Research Support: None - Speakers Bureau/Honoraria:
More informationA physiological model of patient-reported breathlessness during daily activities in COPD
Eur Respir Rev 2009; 18: 112, 66 79 DOI: 10.1183/09059180.00000809 CopyrightßERSJ Ltd 2009 REVIEW A physiological model of patient-reported breathlessness during daily activities in COPD C.J. Jolley and
More informationPulmonary Rehabilitation Focusing on Rehabilitative Exercise Prof. Richard Casaburi
Pulmonary Rehabilitation 1 Rehabilitation Clinical Trials Center Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Torrance, California, USA Historical perspective on rehabilitative
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationExercise Respiratory system Ventilation rate matches work rate Not a limiting factor Elite athletes
Respiratory Exercise Response Chapter 11 Exercise Respiratory system Ventilation rate matches work rate Not a limiting factor Elite athletes Submaximal (
More informationExercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute
Exercise-Induced Bronchospasm Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute EIB Episodic bronchoconstriction with exercise May be an exacerbation
More informationRespiratory Subcommittee of PTAC meeting held 5 February (minutes for web publishing)
Respiratory Subcommittee of PTAC meeting held 5 February 2010 (minutes for web publishing) Respiratory Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationEXERCISE LIMITATION IN MILD COPD: THE ROLE OF RESPIRATORY MECHANICAL FACTORS
EXERCISE LIMITATION IN MILD COPD: THE ROLE OF RESPIRATORY MECHANICAL FACTORS By Roberto Carlos Chin A thesis submitted to the Physiology Graduate Program in the Department of Biomedical and Molecular Sciences
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationClinical pulmonary physiology. How to report lung function tests
Clinical pulmonary physiology or How to report lung function tests Lung function testing A brief history Why measure? What can you measure? Interpretation/ reporting Examples and case histories Exercise
More informationExertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing
SERIES EXERTIONAL DYSPNOEA Exertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing Denis E. O Donnell 1, Amany F. Elbehairy 1,2, Azmy Faisal 1,3, Katherine A. Webb 1, J. Alberto
More informationReview Article Inspiratory Capacity during Exercise: Measurement, Analysis, and Interpretation
Hindawi Publishing Corporation Pulmonary Medicine Volume 2013, Article ID 956081, 13 pages http://dx.doi.org/10.1155/2013/956081 Review Article Inspiratory Capacity during Exercise: Measurement, Analysis,
More information#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA
Where There s Smoke There s Obstruction Stephen G. Basheda, D.O., F.C.C.P. 1 Disclosures Dr. Basheda is an independent contractor for AstraZeneca Pharmaceuticals, LP and GlaxoSmithKline and on the speaker
More informationBronchial Provocation Results: What Does It Mean?
Bronchial Provocation Results: What Does It Mean? Greg King 1 Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards 2065 2 Woolcock Institute of Medical Research and Sydney Medical
More informationSpirometry. Obstruction. By Helen Grim M.S. RRT. loop will have concave appearance. Flows decreased consistent with degree of obstruction.
1 2 Spirometry By Helen Grim M.S. RRT 3 4 Obstruction loop will have concave appearance. Flows decreased consistent with degree of obstruction. Volumes may be normal, but can decrease with severity of
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationCOPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK Presenter Disclosures Wisia Wedzicha All disclosures prior
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationQuestion by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)
Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD) A Pulmonary Diagnosis Form is filled out by the reviewer for all medical records that are sent to them for review by the CSCC.
More informationEffects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
ORIGINAL ARTICLE COPD Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD Denis E. O Donnell 1, Richard Casaburi 2, Peter Frith 3, Anne Kirsten 4, Dorothy De
More informationPulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):
Pulmonary Pearls Christopher H. Fanta, MD Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Medical Pearls Definition: Medical fact that is
More informationContent Indica c tion Lung v olumes e & Lung Indica c tions i n c paci c ties
Spirometry Content Indication Indications in occupational medicine Contraindications Confounding factors Complications Type of spirometer Lung volumes & Lung capacities Spirometric values Hygiene &
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationRecognizing and Correcting Patient-Ventilator Dysynchrony
2019 KRCS Annual State Education Seminar Recognizing and Correcting Patient-Ventilator Dysynchrony Eric Kriner BS,RRT Pulmonary Critical Care Clinical Specialist MedStar Washington Hospital Center Washington,
More informationExercise 7: Respiratory System Mechanics: Activity 1: Measuring Respiratory Volumes and Calculating Capacities Lab Report
Exercise 7: Respiratory System Mechanics: Activity 1: Measuring Respiratory Volumes and Calculating Capacities Lab Report Pre-lab Quiz Results You scored 100% by answering 5 out of 5 questions correctly.
More informationPULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests
PULMONARY FUNCTION TESTING Wyka Chapter 13 Various AARC Clinical Practice Guidelines Purposes of Pulmonary Tests Is lung disease present? If so, is it reversible? If so, what type of lung disease is present?
More informationCoexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis
Volumes: IRV inspiratory reserve volume Vt tidal volume ERV expiratory reserve volume RV residual volume Marcin Grabicki Department of Pulmonology, Allergology and Respiratory Oncology Poznań University
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationVariation in lung with normal, quiet breathing. Minimal lung volume (residual volume) at maximum deflation. Total lung capacity at maximum inflation
r Total lung capacity at maximum inflation Variation in lung with normal, quiet breathing Volume of lungs at end of normal inspiration (average 2,200 ml) Minimal lung volume (residual volume) at maximum
More informationPulmonary and Critical Care Year in Review
Pulmonary and Critical Care Year in Review Heath E Latham, MD Assistant Professor University of Kansas Dept of Internal Medicine Division of Pulmonary and Critical Care None Disclosure Lung Cancer Screening
More informationAcute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma
Acute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma Talk Outline Case Delivery of bronchodilators Meter-dose inhalers and spacers Continuous nebulization
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationPeripheral mechanisms of dyspnoea
Peripheral mechanisms of dyspnoea Miriam Johnson 2012 A complex interaction respiratory motor areas of the brain receive information and commands required ventilation ascending copy of descending motor
More informationDescriptors of Breathlessness in Patients With Cancer and Other Cardiorespiratory Diseases
182 Journal of Pain and Symptom Management Vol. 23 No. 3 March 2002 Original Article Descriptors of Breathlessness in Patients With Cancer and Other Cardiorespiratory Diseases Andrew Wilcock, DM, FRCP,
More informationEvaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD
c Additional Methods data are published online only at http:// thorax.bmj.com/content/vol64/ issue3 1 Respiratory Investigation Unit, Department of Medicine, Queen s University and Kingston General Hospital,
More informationModulation of operational lung volumes with the use of salbutamol in COPD patients accomplishing upper limbs exercise tests
Respiratory Medicine (2009) 103, 251e257 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Modulation of operational lung volumes with the use of salbutamol in COPD patients
More informationTARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS
TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Recommendation PULMONARY FUNCTION TESTING (SPIROMETRY) Conditional: The Expert Panel that spirometry measurements FEV1,
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationVentilator Dyssynchrony - Recognition, implications, and management
Ventilator Dyssynchrony - Recognition, implications, and management Gavin M Joynt Dept of Anaesthesia & Intensive Care The Chinese University of Hong Kong Dyssynchrony Uncoupling of mechanical delivered
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More information